About
Claudia Mitchell is a biopharma executive, scientist, and entrepreneur with more than 20 years of experience across cell therapy, gene therapy, and RNA therapeutics. She previously served as Senior Vice President of Portfolio Strategy at Astellas Pharma and was CEO and co-founder of Universal Cells until its acquisition by Astellas in 2019 for over $100 million. She now holds board leadership roles including Chair of Cellerys and director roles at Coave Therapeutics and Adocia, and is also identified by Cellerys as CEO of Savantia.
Areas of interest
biotechcell therapygene therapyregenerative medicineRNA therapeuticsportfolio strategyneurodegenerative diseaseophthalmologymultiple sclerosis